For an adult who has completed alcohol detoxification and been opioid‑free for at least 7–10 days, what is the recommended Vivitrol (extended‑release naltrexone) dosing schedule and what pre‑injection urine drug screening should be performed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Vivitrol Dosing and Pre-Injection Drug Screening for Alcohol Treatment

For adults completing alcohol detoxification, Vivitrol (extended-release naltrexone) is administered as 380 mg intramuscularly into the gluteal muscle every 4 weeks (monthly), and patients must be opioid-free for a minimum of 7–10 days before the first injection to prevent precipitated withdrawal. 1

Dosing Schedule

Standard Dosing:

  • 380 mg deep intramuscular gluteal injection every 4 weeks (monthly) 1
  • Alternate buttocks with each subsequent injection
  • Must be administered by a healthcare provider using the customized needles provided in the carton (1½-inch or 2-inch needles depending on body habitus)
  • No oral naltrexone pretreatment is required before initiating Vivitrol 1

Critical Pre-Treatment Requirements:

  • Patients must be abstinent from alcohol at the time of initial administration 1
  • Patients should be able to abstain from alcohol in an outpatient setting prior to initiation 1
  • Minimum 7–10 days opioid-free is mandatory before first injection to avoid severe precipitated opioid withdrawal that may require hospitalization 1

Pre-Injection Drug Screening

Mandatory Opioid Screening:

The most critical pre-injection testing is urine drug screening for opioids to confirm the patient has been opioid-free for at least 7–10 days. This is essential because naltrexone is a pure opioid antagonist that will precipitate severe withdrawal in anyone with opioids in their system 1.

Key Testing Considerations:

  • Standard enzyme-linked immunoassays may not detect hydrocodone, fentanyl, hydromorphone, oxycodone, or methadone reliably 2
  • Consider gas chromatography or mass spectrometry for comprehensive opioid detection if there is any concern about recent opioid use 2
  • False-negative results can occur from tampering, so clinical assessment remains important 2

Additional Baseline Testing:

  • Liver function tests (LFTs) at baseline, then every 3–6 months, as naltrexone has been associated with hepatocellular injury at supratherapeutic doses 3
  • This is particularly important since the patient has alcohol use disorder and may have underlying liver disease 4

Clinical Implementation Algorithm

Step 1: Confirm Eligibility

  • Patient has completed alcohol detoxification
  • Patient is not actively drinking
  • Patient is opioid-free for ≥7–10 days (verify by history AND urine drug screen)

Step 2: Baseline Testing

  • Comprehensive urine drug screen (preferably with confirmatory testing for synthetic opioids)
  • Baseline liver function tests
  • Assess for contraindications (current opioid use, acute hepatitis, liver failure)

Step 3: First Injection

  • Administer 380 mg IM gluteal injection
  • Provide psychosocial support (counseling is essential component) 1, 5
  • Educate patient about overdose risk if they relapse to opioid use while on naltrexone

Step 4: Ongoing Management

  • Monthly injections (every 4 weeks)
  • Monitor LFTs every 3–6 months 3
  • Continue psychosocial support throughout treatment 4

Critical Safety Warnings

Opioid Sensitivity: Patients on Vivitrol will have increased sensitivity to opioids if they attempt to use them. This creates significant overdose risk, particularly:

  • When the next dose is due
  • If a dose is missed
  • After treatment discontinuation 1

Overdose Prevention: At each injection visit, discuss and ensure access to naloxone (opioid overdose reversal agent) for emergency use, as patients may relapse after treatment ends or miss doses 1.

Hepatotoxicity: Naltrexone is not recommended in patients with active alcoholic liver disease due to risk of hepatic injury 6. However, guidelines support its use in combination with counseling for alcohol dependence in those who achieve abstinence 4.

Evidence for Efficacy

The evidence strongly supports Vivitrol's effectiveness when patients are already abstinent. In the pivotal trial, among patients who were completely abstinent during the week prior to first injection, Vivitrol 380 mg produced greater reductions in drinking days and heavy drinking days compared to placebo 1. However, these benefits were not evident among patients who were actively drinking at treatment initiation 1, reinforcing the importance of achieving abstinence before starting treatment.

Treatment retention and adherence remain challenges—approximately 44% of patients complete all scheduled injections in real-world settings 7, though rates are higher in structured research settings. Combining Vivitrol with case management and psychosocial support significantly improves outcomes 8, 9.

Related Questions

What are the guidelines for initiating Vivitrol (naltrexone) treatment?
What is the dosing schedule, indications, contraindications, and monitoring for Vivitrol (extended‑release naltrexone) injection?
Should oral naltrexone be discontinued before initiating Vivitrol (extended-release injectable naltrexone)?
How many days must a patient be opioid-free before starting oral naltrexone and before the long‑acting injectable formulation?
Can naltrexone be used on an as-needed (PRN) basis for treating alcohol use?
Why must hyper‑diluted Radiesse (calcium hydroxylapatite) be placed in the intradermal or subdermal plane, and what safety risks arise if it is injected deeper?
Does a left ventricular assist device (LVAD) improve cardiac output in a patient with non‑ischemic biventricular cardiomyopathy and an ejection fraction of 8%?
For a dementia patient with sundowning, verbal aggression, wandering into other residents' rooms, and agitation beginning around 4 pm who is difficult to redirect and is currently taking buspirone 15 mg twice daily, quetiapine fumarate 50 mg each morning, and trazodone 100 mg at bedtime, what additional therapy should be added to manage his behavioral symptoms?
What is the clinical significance of positive foraminal compression signs and positive nerve‑root tension signs?
Which antibiotic is appropriate for an adult with an uncomplicated urinary tract infection and a presumptive bacterial gastrointestinal infection?
How should post‑infectious inflammatory changes on chest X‑ray (e.g., organizing pneumonia) be managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.